HBD1 peptide

HBD1 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-CKHHLGLEEPKKLR-OH

H-Cys-Lys-His-His-Leu-Gly-Leu-Glu-Glu-Pro-Lys-Lys-Leu-Arg-OH

14

95.88%

C₇₄H₁₂₆N₂₄O₁₉S

1688

Synthetic

Powder

The peptide HBD1 is a synthetic peptide that contains the heparin-binding domain 1 of human insulin-like growth factor binding protein-2 (IGFBP-2). It has been shown to stimulate bone formation and increase bone mass in ovariectomized rats. There are some key points about its application prospect: Peptide HBD1 has potential as a therapeutic agent for treating osteoporosis and other bone-related disorders. The peptide has been shown to be effective in increasing bone mass in estrogen-deficient animals, which suggests that it may be useful for treating postmenopausal osteoporosis. Peptide HBD1 may be used in combination with other bone-building agents, such as parathyroid hormone (PTH), to enhance their effects. The pegylated form of peptide HBD1 has been shown to have a reversing dose response curve in stimulating osteoblast differentiation, which suggests that it may have potential as a drug delivery system for other bone-building agents.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Xi G, Wai C, Rosen CJ, Clemmons DR. A peptide containing the receptor binding site of insulin-like growth factor binding protein-2 enhances bone mass in ovariectomized rats. Bone Res. 2018 Aug 14;6:23. doi: 10.1038/s41413-018-0024-9. PMID: 30109160; PMCID: PMC6089876.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.